e-learning resources

ERS International Congress, Milan 2017

Browse by day: Saturday, 09.09.2017 Sunday, 10.09.2017 Monday, 11.09.2017 Tuesday, 12.09.2017 Wednesday, 13.09.2017		Sponsored symposia: Industry Evening Symposium at ERS 2017: “Evolving Concepts in Asthma with Type 2 Inflammation: the Role of Biologics”

Citations should be made in the following way: Authors. Title. Eur Respir J 2017; 50: Suppl. 61, abstract number.

Discussion of vaccines, biomarkers and risk factors analysis

Poster Discussion
Chairs: S. Aliberti (Milan, Italy), A. Anzueto (San Antonio, United States of America)

Download all media

Download all media

Changes in pathogens and pneumococcal serotypes causing community-acquired pneumonia in The Netherlands S. Vestjens (Nieuwegein, Netherlands)
Genetic Analyses of Multidrug-Resistant Streptococcus pneumoniae Serogroup 19 CC320/271 Clone in China J. Zhang (Shanghai, China)
Impact of pneumococcal vaccination in children in the distribution of serotypes in bacteriemic pneumococcal pneumonia in adults A. ARTARAZ (Galdakao (Bizkaia), Spain)
Efficiency of specific prevention of pneumococcal infection at patients from risk groups in Krasnoyarsk region A. Kraposhina (Krasnoyarsk, Russian Federation)
Effectiveness data on prevention of COPD exacerbations with 13-valent pneumococal conjugate vaccine (PCV13) J. Gonzalez Ruiz (Salamanca, Spain)
Pneumococcal vaccination in interstitial lung disease patients receiving systemic immunosuppressive treatment K. Kuronuma (Sapporo, Japan)
Efficacy of vaccination to prevent pneumococcal infection in organized communities I. Shubin (Moscow, Russian Federation)
Effectiveness of the 23-valent pneumococcal polysaccharide vaccine for the patients with lung comorbidities; a single center, retrospective, self-controlled case series study M. Aoshima (Kamogawa, Japan)
A randomized, open-label, parallel design study to compare the immunogenicity of simultaneous administration versus sequential administration of quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in the elderly K. Nakashima (Kamogawa, Japan)
Osteopontin role in community-Acquired Pneumonia (CAP). R. Sharshar (Tanta, Egypt)
Association between biomarkers at discharge and risk of readmission after community-acquired pneumonia – a retrospective cohort study P. Petersen (København, Denmark)
Interpretation of biomarkers at emergency department depends on onset of symptoms in community-acquired pneumonia R. Méndez (VALENCIA, Spain)
Diagnosis on community-acquired pneumonia (CAP) in patients with congestive heart failure (CHF) S. Avdeev (Moscow, Russian Federation)
Intrahospital cardiovascular complications in severe community-acquired pneumonia A. Cilli (Antalya, Turkey)
NON BACTERIEMIC PNEUMOCOCCAL PNEUMONIA: GENERAL CHARACTERISTICS AND PREDISPOSING FACTORS FOR POOR OUTCOME L. Serrano Fernandez (Bilbao (Bizkaia), Spain)
Inter-hospital variation in resource utilization of diagnostic and follow-up biomarkers in adult community-acquired pneumonia S. Vestjens (Nieuwegein, Netherlands)
Studying the association between mortality in patients requiring hospital admission for Community Acquired Pneumonia and pre-hospital antibiotic treatment in primary care B. Chakrabarti (Liverpool, United Kingdom)

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.